The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sukoian G.V.

NII obshcheĭ patologii i patofiziologii RAMN

Oganov R.G.

Gosudarstvennyĭ nauchno-issledovatel'skiĭ tsentr profilakticheskoĭ meditsiny, Moskva

Signal mechanisms of cardioprotection and new strategies for heart failure prevention and treatment

Authors:

Sukoian G.V., Oganov R.G.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2012;15(2): 23‑32

Read: 1848 times

Download PDF (RU)
Contact the author
Table of contents

SIGNAL MECHANISMS OF CARDIOPROTECTION AND NEW STRATEGIES FOR HEART FAILURE PREVENTION AND TREATMENT
SIGNAL MECHANISMS OF CARDIOPROTECTION AND NEW STRATEGIES FOR HEART FAILURE PREVENTION AND TREATMENT

To cite this article:

Sukoian GV, Oganov RG. Signal mechanisms of cardioprotection and new strategies for heart failure prevention and treatment. Russian Journal of Preventive Medicine. 2012;15(2):23‑32. (In Russ.)

 
Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The pote­ntials of the six-minute walking test in clinical practice auto­matization and adva­nced features. Russian Journal of Preventive Medi­cine. 2024;(12):122-127
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Clinical and phenotypical profiles of patients with chro­nic heart failure with preserved ejection fraction. Russian Journal of Preventive Medi­cine. 2025;(1):83-88
The effect of the iron III poly­saccharide complex use on the cyto­kines, natriuretic peptide and erythropoietin levels in patients with chro­nic heart failure acco­mpanied with anemia. Russian Journal of Preventive Medi­cine. 2025;(3):80-86
Labo­ratory biomarkers for the prognosis of chro­nic heart failure. Labo­ratory Service. 2024;(3):5-16
Diaphragm dysfunction as a prognostic criterion of exte­rnal respiratory impairment and nece­ssary extracorporeal membrane oxygenation in patients with chro­nic heart failure. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):38-45
Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chro­nic heart failure combined with obesity. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):53-60
Prognostic significance of NT-proBNP and sST2 in patients with chro­nic heart failure and redu­ced ejection fraction after previous deco­mpensation. Russian Cardiology Bulletin. 2025;(1):49-56
Dyna­mics of vector electrocardiography para­meters in patients with chro­nic heart failure under opti­mal drug therapy. Russian Cardiology Bulletin. 2025;(1):57-63
Mito­chondrial cyto­protectors in complex therapy of chro­nic heart failure in patients with meta­bolic syndrome or type 2 diabetes mellitus: suba­nalysis of the INDI­KOR study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):566-576
Abstract:

Keywords:

cardioprotection
chronic heart failure
signal mechanisms
adenocin

Authors:

Sukoian G.V.

NII obshcheĭ patologii i patofiziologii RAMN

Oganov R.G.

Gosudarstvennyĭ nauchno-issledovatel'skiĭ tsentr profilakticheskoĭ meditsiny, Moskva

Close metadata

References:

  1. Oganov R.G. Razvitie profilakticheskoi kardiologii v Rossii. Kardiovask terap i prof 2004; 3 :1-3: 10-14.
  2. Ahmed A., Young J.B., Gheorghiade M. The underuse of digoxin in heart failure, and approahes to appropriate use. Can Med Ass J 2007; 176: 5: 641-643.
  3. Diez J., Ertl G. A translational approach to myocardial remodelling. Cardiovasc Res 2009; 81: 409-411.
  4. Ellison G.M., Waring C.D., Vicinanza C., Torella D. Physiological cardiac remodelling in response to endurance exercise training: cellular and molecular mechanisms. Heart 2012; 98: 5-10.
  5. Erekowitz J.A., Kaul P., Bakal A.J., Quan H., McAlister F.A. Trends in heart failure: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics? Eur Heart Fail 2011; 13: 142-147.
  6. Dzau V.J., Antman E.M., Black H.R., Hayes D.L., Manson J.E., Plutzky J., Popma J.J., Stevenson W. The sardiovascular disease sontinuum validated: clinical evidence of improved patient outcomes. Part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114: 2850-2870.
  7. Fox K.A. Courage to change practice? Revascularisation in patients with stable coronary artery disease. Heart 2009; 95: 689-692.
  8. Hilfeker-Kleiner D., Landmesser U., Drexler H. Molecular mechanism of heart failure. J Am Coll Cardiol 2006; 48: 9: Suppl: A56-A66.
  9. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., Oates J.A., Rahko P.S. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
  10. Gilstrap L.G., Wang Thomas J. Biomarkers and cardiovascular risk assessment for primary prevention: An Update. Clin Chem 2012; 58: 1: 72-82.
  11. Bokeriya L.A., Malikov V.E., Arzumanyan E.A., Kezeli T.D., Sukoyan G.V. Ratsional'naya farmakorrektsiya sindroma sistemnogo vospalitel'nogo otveta u bol'nykh so snizhennoi sokratitel'noi funktsiei serdtsa. Gematologiya 2008; 2: 45-53.
  12. Heymans S., Hirsch E., Anker S.D., Aukrust P., Balligand J.L., Cohen-Tervaert J.W., Drexler H., Filippatos G., Felix S.B., Gullestad L., Hilfiker-Kleiner D., Janssens S. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 119-129.
  13. Hori M., Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 2009; 81: 3: 457-464.
  14. Kominsky D.J., Campbell E.L., Colgan S.P. Metabolic Shifts in Immunity and Inflammation. J Immunol 2010; 184: 4062-4068.
  15. Delcayre C., Silvestre J.S., Garnier A., Oubenaissa A., Cailmail S., Tatara E. Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000; 57: 1346-1351.
  16. Dhalla N.S., Dent M.R., Tappia P.S., Sethi R., Barta J., Goyal R.K. Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure. Cardiovasc Pharmacol Ther 2006; 11: 31-45.
  17. Dhalla N.S., Saini-Chohan H.K., Rodriguez-Leyva D., Elimban V., Dent M.R., Tappia P.S. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res 2009; 81:429-438.
  18. Taegtmeyer H. Tracing Cardiac Metabolism In Vivo: One Substrate at a Time. J Nucl Med 2010; 51: Suppl 1: 80S-87S.
  19. Woo A., Wang T., Zeng X., Zhu W., Abernethy D.R., Wainer I.W., Xia R.P. Stereochemistry of an agonist determines coupling preference of Β2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol 2009; 75: 158-165.
  20. Ingwall J.S. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009; 81: 412-419.
  21. Dai D.F., Hsieh E.J., Liu Y., Chen T., Beyer R.P., Chin M.T., Maccoss M.J., Rabinovitch P.S. Mitochondrial proteome remodelling in pressure overload-induced heart failure: the role of mitochondrial oxidative stress. Cardiovasc Res 2012; 93: 79-88.
  22. Karsanov N.V., Galenko-Yaroshevskii P.A., Sukoyan G.V. Serdechnye glikozidy. M 2004; 400.
  23. Sumandea P., Steinberg F. Redox signaling and cardiac sarcomeres. J Biol Chem 2011; 286: 9921-9927.
  24. Sukoyan G.V., Antelava N.A. Ratsional'naya farmakoterapiya sindroma sistemnogo vospalitel'nogo otveta pri tyazheloi nedostatochnosti serdtsa v eksperimente. Byul eksper biol 2009; 147: 4: 411-414.
  25. Sukoyan G.V., Andriadze N.A., Guchua E.I., Karsanov N.V. Vliyanie nikotinamidadenindinukleotida na vosstanovlenie pula adenilovykh nukleotidov, potentsiala fosforilirovaniya i stimulyatsiyu apoptoza v otdalennom periode reperfuzionnykh povrezhdenii miokarda. Byul eksp biol 2005; 139: 1: 53-56.
  26. Sukoyan G.V., Gongadze N.V. Sravnitel'naya effektivnost' terapevticheskogo deistviya adenotsina i kardiotonicheskikh sredstv neglikozidnoi prirody pri khronicheskoi nedostatochnosti serdtsa v pokoe i pri povyshennoi nagruzke na serdtse. Byul eksp biol 2010; 149: 6: 653-656.
  27. Sukoyan G.V., Gongadze N.V. Mekhanizm kardioprotektornogo deistviya adenotsina i kardiotonicheskikh sredstv neglikozidnoi prirody pri khronicheskoi nedostatochnosti serdtsa v eksperimente. Byul eksp biol 2010; 150: 11: 541-544.
  28. Davidson S.M., Duchen M.R. Endothelial mitochondria - Contributing to vascular function and disease. Circ Res 2007; 100: 1128-1141.
  29. Gao Sh., Long C.L., Wang R.H., Wang H. KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc. Res. 2009; 83: 444-456.
  30. Li Y., Dash R.K., Kim J, Saidel G.M., Cabrera M.E. Role of NADH/NAD transport activity and glycogen store on skeletal muscle energy metabolism during exercise: in silico studies. Am J Physiol 2009; 296: C25-C46.
  31. Machackova J., Sanganalmath S.K., Barta J., Dhalla K.S., Dhalla N.S. Amelioration of cardiac remodeling in congestive heart failure by beta-adrenoceptor blockade is associated with depression in sympathetic activity. Cardiovasc Toxicol 2010; 10: 9-16.
  32. Christians E.S., Benjamin I.J. Proteostasis and REDOX state in the heart. Am J Physiol Heart Circ Physiol 2012; 302: H24-H27.
  33. Lombes M., Alfaidy N., Eugene E., Lessana A., Farman N., Bonvalet J.P. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175-182.
  34. Szwejkowski B.R., Rekhraj S., Elder D.H., Struthers A. Update on heart failure. Br J Diabet Vasc Dis 2011; 11: 25-30.
  35. Garlid K.D., Costa A.D., Quinlan C.L., Pierre S.V., Dos Santos P. Cardioprotective signaling to mitochondria. J Mol Cell Cardiol 2009; 46: 858-866.
  36. Giordano F.J. Oxygen: both a passenger and a biological determinant in the vasculature. Arterioscler Thromb Vasc Biol 2010; 30: 641-642.
  37. Arrigoni E., Crocker A.J., Saper C.B., Greene R.W., Scammell T.E. Deletion of presynaptic adenosine A1 receptors impairs the recovery of synaptic transmission after hypoxia. Neuroscience 2005; 132: 575-580.
  38. Coons J.C., McGraw M., Murali S. Pharmacotherapy for acute heart failure syndromes. Health Syst Am J Pharm 2011; 68: 21-35.
  39. Madamanchi N.R., Runge M.S. Mitochondrial dysfunction in atherosclerosis. Circ Res 2007; 100: 4: 460-473.
  40. Negro A., Dodge-Kafka K., Kapiloff M.S. Signalosomes as therapeutic targets. Prog Pediatr Cardiol 2008; 25: 51-56.
  41. Beauloye C., Bertrand L., Horman S., Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 2011; 90: 2: 224-233.
  42. Malekar P., Hagenmueller M., Anyanwu A., Buss S., Streit M.R., Weiss C.S., Wolf D. Wnt signaling is critical for maladaptative cardiac hypertrophy and accelerates myocardial remodeling. Hypertension 2010; 55: 939-945.
  43. Pillai J.B., Isbatan A., Imai S.-I., Gupta M.P. Poly(ADP-ribose)polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2α deacetylase activity. J Biol Chem 2005; 280: 43121-43130.
  44. Pillai J.B., Sundaresan N.R., Kim G., Gupta M., Rajamohan S.B., Pillai J.B., Samant S., Ravindra P.V., Isbatan A., Gupta M.P. Exogenous NAD blocks Cardiac Hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem 2010; 285: 3133-3144.
  45. Gelpi R.J., Park M., Gao S., Dhar S., Vatner D.E., Vatner S.F. Apoptosis in severe, compensated pressure overload predominates in nonmyocytes and is related to the hypertrophy but not function. Am J Physiol Heart Circ Physiol 2011; 300: H1062-H1068.
  46. Dorn G.W., Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. Am J Resp Crit Care Med 2011; 183: 396-404.
  47. Go'mez G., Sitkovsky M.V. Differential requirement for A2A and A3 adenosine receptors for the protective effect of inosine in vivo. Blood 2003; 102: 4472-4478.
  48. Guinzberg R., Cortes D., Diaz-Cruz A., Riveros-Rosas H., Villalobos-Molina R., Pina E. Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors. Am J Physiol Endocrinol Metab 2006; 290: E940-E951.
  49. Apostolakis St., Lip Y.H. Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair? Cardiovasc Res 2010; 85: 649-660.
  50. Ying W. Therapeutic potential of NAD for neurological diseases. Future Neurol 2007; 2: 2: 129-132.
  51. Hingtgen S.D., Li K.Z., Tian X., Sharma R.V., Davisson R.L. Superoxide scavenging and Akt inhibition in myocardium ameliorate pressure overload-induced NF-(kappa)B activation and cardiac hypertrophy. Physiol. Genomics 2010; 41: 2: 127-136.
  52. Szabo' G., Liaudet L., Hagl S., Szabo' C. Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res 2004; 61: 471-480.
  53. Szabo' G., Stumpf N., Radovits T., Sonnenberg K., Gerö D., Hagl S., Szabo C., Bährle S. Effects of inosine on reperfusion injury after heart transplantation. Eur J Cardiothorac Surg 2006; 30: 96-102.
  54. Virag L., Szabo C. Purines inhibit poly(ADP-ribose)polymerase activation and modulate oxidant-induced cell death. FASEB J 2001; 15: 99-107.
  55. Kometiani P., Liu L., Askari A. Digitalis-induced signaling by Na+,K+ATPase in human breast cancer cells. Mol Pharmacol 2005; 67: 929-936.
  56. Scheiner-Bobis G. The Na+, K+-ATPase: more than just a sodium pump. Cardiovasc Res 2011; 89: 6-8.
  57. Shapiro J.I., Tian J. Signaling through the Na/K-ATPase: implications for cardiac fibrosis. Am J Physiol Heart Circ Physiol 2011; 300: H29-H30.
  58. Abel E.D., Doenst T. Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc Res 2011; 31: 2-9.
  59. Pierre S.V., Belliard A., Sottejeau Y. Modulation of Na+-K+-ATPase cell surface abundance through structural determinants on the α1-subunit. Am J Physiol Cell Physiol 2011; 300: C42-C48.
  60. Sadoshima J. Sirt3 Targets mPTP and Prevents Aging in the Heart. Aging (Albany New York) 2011; 3: 12-13.
  61. Spicer J., Ashworth A. LKB1 Kinase: master and commander of metabolism and polarity. Curr Biol 2004; 14: 10: R383-R385.
  62. Yang C.M., Lin M.I., Hsieh H.L., Sun C.C., Ma Y.H., Hsiao L.D. Bradykinin-induced p42/p44 MAPK phosphorylation and cell proliferation via Src, EGF receptors, and PI3-K/Akt in vascular smooth muscle cells. J Cell Physiol 2005; 203: 538-546.
  63. Pasdois P.P., Quinlan C.L., Rissa A. Ouabain protects rat hearts against ischemia involving src kinase, mitoKATP, and ROS. Am J Physiol Heart Circ Physiol 2007; 292: H1470-H1478.
  64. Woodcock E.A., Du X.J., Reichelt M.E., Graham M. Cardiac α1-adrenergic drive in pathological remodeling. Cardiovasc Res 2008; 77: 452-462.
  65. Bers D.M. Calcium cycling and signaling in cardiac myocytes. Ann Rev Physiol 2008; 70: 23-49.
  66. Belenky P., Bogan K.L., Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci 2007; 32: 12-19.
  67. Koch-Nolte F., Haag F., Guse A.H., Lund F., Ziegler M. Emerging roles of NAD+ and its metabolites in cell signaling. Sci Signal 2009; 2: 1-8.
  68. Wang S., Xing Z., Vosler P.S., Yin H., Li W., Zhang F., Signore A.P., Stetler R.A., Gao Y., Chen J. Cellular NAD replenishment confers marked neuroprotection against ischemic cell death. Stroke 2008; 39: 2587-2595.
  69. Peart J.N., Headrick J.P. Clinical cardioprotection and the value of conditioning responses. Am J Physiol Heart Circ Physiol 2009; 296: H1705-H1720.
  70. Hasko G., Sitkovsky M.V., Szabo C. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 2004; 25: 3: 152-157.
  71. Pacher P., Szabo C. Role of poly(ADP-ribose)polymerase-1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP-1 inhibitors. Cardiovasc Drug Rev 2007; 25: 235-260.
  72. Hasenfuss G., Teerlink J.R. Cardiac inotropes: current agents and future directions. Eur Heart J 2011; 32: 15: 1838-1845.
  73. Xia W., Wang Z., Wang Q., Han J., Zhao C., Hong Y., Zeng L., Tang L., Ying W. Roles of NAD+/NADH and NADP+/NADPH in cell death. Curr Pharm Design 2009; 15: 12-19.
  74. Gosta A.T., Garlid K.D. sGMP signaling in pre- and post-conditioning: the role of mitochondria. Cardiovasc Res 2008; 77: 344-352.
  75. Li Y., Dash R.K., Kim J., Beard D.A., Saidel G.M. Role of NADH/NAD transport activity and glycogen store on skeletal muscle energy metabolism during exercise: in silico studies. Am J Physiol 2009; 296: C25-C46.
  76. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 2008; 10: 2: 179-206.
  77. Alano C.C., Garnier P., Ying W., Higashi Y., Kauppinen T.M., Swanson R.A. NAD+ depletion is necessary and sufficient for Poly(ADP) Ribose polymerase-1 mediated neuronal death. J Neurosci 2010; 30: 2967-2978.
  78. Chini E.N. CD38 as a regulator of cellular NAD; a novel potential pharmacological target for metabolic condition. Curr Pharm Design 2009; 16: 57-63.
  79. Bruzzone S., Guida L., Zocchi E., Franco L., De Flora A. Connexin 43 hemi channels mediate Ca2+-regulated transmembrane NAD+ fluxes in intact cells. FASEB J 2001; 15: 10-12.
  80. De Flora A., Zocchi E., Guida L., Franco L., Bruzzone S. Autocrine and paracrine calcium signaling by the CD38/NAD+/cyclic ADP-ribose system. Ann NY Acad Sci 2004; 1028: 176-191.
  81. Cantó C., Auwerx J. Targeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD+? Pharmacol Rev 2012; 64: 1: 166-187.
  82. Sukoyan G.V., Kavadze I.K. Vliyanie lekarstvennogo sredstva nadtsin na sostoyanie sistemy energeticheskogo obespecheniya i skorost' apoptoza pri ishemicheski reperfuzionnykh povrezhdeniyakh miokarda. Byul eksper biol 2008; 146: 9: 297-300.
  83. Bokeriya L.A., Malikov V.E., Sukoyan G.V., Arzumanyan M.A. Sposoby kardioprotektsii u bol'nykh ishemicheskoi bolezn'yu serdtsa s disfunktsiei levogo zheludochka. M 2008.
  84. Malikov V.E., Evsikov E.M., Kutuzova T.G., Rogava M.A. Farmakologicheskaya korrektsiya simptomov i remodelirovanie serdtsa pri refrakternykh formakh khronicheskoi serdechnoi nedostatochnosti s disfunktsiei levogo zheludochka. Ros kardiol zhurn 2008; 5: 56-62.
  85. Rogava M.A., Bochorishvili T., Gongadze N.V. Farmakologicheskaya korrektsiya sistemnogo vospalitel'nogo otveta u bol'nykh s khronicheskoi serdechnoi nedostatochnost'yu. Allergol i immunol 2008; 5: 516-519.
  86. Malikov V.E., Arzumanyan M.A., Donetskaya O.P. Farmakologicheskaya korrektsiya induktsii pro- i protivovospalitel'nykh tsitokinov i sostoyaniya sistemy energeticheskogo obespecheniya u bol'nykh ishemicheskoi bolezn'yu serdtsa, oslozhnennoi khronicheskoi serdechnoi nedostatochnost'yu. Kardiovask ter i prof 2011; 10: 5: 37-42.
  87. Thaddeus T., Li S., Li X. Surprising sirtuin crosstalk in the heart. Aging 2010; 2: 3: 129-132.
  88. Ngarmukos Ch., Grekin R.J. Nontraditional aspects of aldosterone physiology. Am J Phys Endocrinol Metab 2001; 281: E1122-E1127.
  89. Edelmann F., Schmidt A.G., Gelbrich G., Binder L., Herrmann-Lingen C., Halle M. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail 2010; 12: 874-882.
  90. Marx G., Blankenfeld A., Panet R., Grodetsky R. Model for the regulation of platelet volume and responsiveness by the trans-membrane Na+/K+-pump. J Cell Physiol 1992; 151: 249-254.
  91. Tomasiak M., Stelmach H., Rusak T., Ciborowski M., Radziwon P. The involvement of Na+/K+-ATPase in the development of platelet procoagulant response. Acta Biochim Polonica 2007; 54: 3: 625-639.
  92. D'Urso G., Frascarelli S., Zucchi R., Biver T., Montali U. Cardioprotection by ouabain and digoxin in perfused rat hearts. Cardiovasc Pharmacol 2008; 52: 4: 333-340.
  93. Schwartz B.G., Levine L.A., Comstock G., Stecher V.J., Kloner R.A. Cardiac Uses of Phosphodiesterase-5 Inhibitors. J Am Coll Cardiol 2012; 59: 9-15.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.